Table 11. Recent reports concerning the use of preoperative TACE in HCC patients who accepted liver transplantation.
| First author | Country | Published year | Recruitment Year | Patient number | Inclusion criteria | Treatment protocol | Patient number | Overall survival rate (%) |
P Value | Tumor-free survival rate (%) |
P value | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 3-year | 5-year | 1-year | 3-year | 5-year | ||||||||||
| Eswaran39 | USA | 2012 | 1999–2008 | 39 | None | LT | 7 | 92% | 77% | 77% | P = 0.28 | — | — | — | — |
| TACE + LT | 28 | 100% | 100% | 82% | — | — | — | — | |||||||
| Seehofer40 | Germany | 2012 | 1989–2008 | 177 | USCF | LT | 106 | 87% | 76% | 67% | P = 0.522 | — | — | — | — |
| TACE + LT | 71 | 92% | 80% | 73% | — | — | — | — | |||||||
| Schaudt41 | Germany | 2009 | 1995–2005 | 27 | None | LT | 12 | 92% | 92% | 61% | P = 0.5 | — | — | — | — |
| TACE + LT | 15 | 100% | 93% | 82% | — | — | — | — | |||||||
| Decaens42 | France | 2005 | 1995–1998 | 200 | None | LT | 100 | 82% | 68% | 59.4% | P > 0.05 | 83% | 75% | 64.1% | P > 0.05 |
| TACE + LT | 100 | 85% | 78% | 59.3% | 80% | 74% | 69.3% | ||||||||
| Yao56 | USA | 2005 | 1999–2002 | 90 | T2–3 | LT | 41 | — | — | — | 91.5% | 80.6% | 80.6% | P = 0.049 | |
| TACE + LT | 85 | — | — | — | 96.4% | 93.8% | 93.8% | ||||||||
| Perez43 | Spain | 2005 | 1986–2001 | 46 | Okuda I-III | LT | 28 | 77.2% | 58.7% | 38.1% | P = 0.56 | 68.2% | 54.2% | 39.5% | P = 0.8 |
| TACE + LT | 18 | 83.3% | 60.5% | 60.5% | 77.8% | 54.3% | 54.3% | ||||||||
| Oldhafer44 | Germany | 1998 | 1993–1996 | 42 | UICC I-IV | LT | 21 | 61.5% | 53.9% | 45.2% | P > 0.05 | 85.2% | 70.3% | 62.0% | 0.782 |
| TACE + LT | 21 | 60.8% | 48.4% | 48.4% | 87.2% | 70.5% | 60.3% | ||||||||
| Present study | China | Present | 2005–2009 | 415 | BCLC 0-A /B | LT | 337 | 91.7% | 79.2% | 68.5% | 0.939 | 85.2% | 70.3% | 62.0% | 0.783 |
| TACE + LT | 78 | 92.3% | 78.2% | 69.2% | 87.2% | 70.5% | 60.2% | ||||||||
BCLC: Barcelona Clinic Liver Cancer; TACE: transarterial chemoembolization; RFA: Radiofrequency ablation; LT: liver transplantation; UCSF: University of California.